Journal
EUROPEAN STROKE JOURNAL
Volume 6, Issue 1, Pages 62-71Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2396987320984003
Keywords
Ischaemic stroke; transient ischaemic attack; recurrence; interleukin-6; C-reactive protein; fibrinogen; prognosis; inflammation
Categories
Funding
- Health Research Board Ireland
- Irish Heart Foundation
Ask authors/readers for more resources
This study conducted a systematic review and meta-analysis on the association between blood inflammatory markers and the risk of recurrent stroke or major vascular events (MVEs) after stroke. The findings indicated that CRP and fibrinogen were associated with recurrent stroke and MVEs, while IL-6 showed some trends but not statistically significant associations. Substantial methodological heterogeneity among studies was identified, highlighting the need for individual-patient pooled analysis and standardization of methods to determine the prognostic role of blood inflammatory markers.
Background Recent randomised trials showed benefit for anti-inflammatory therapies in coronary disease but excluded stroke. The prognostic value of blood inflammatory markers after stroke is uncertain and guidelines do not recommend their routine measurement for risk stratification. Methods We performed a systematic review and meta-analysis of studies investigating the association of C-reactive protein (CRP), interleukin-6 (IL-6) and fibrinogen and risk of recurrent stroke or major vascular events (MVEs). We searched EMBASE and Ovid Medline until 10/1/19. Random-effects meta-analysis was performed for studies reporting comparable effect measures. Results Of 2,515 reports identified, 39 met eligibility criteria (IL-6, n = 10; CRP, n = 33; fibrinogen, n = 16). An association with recurrent stroke was reported in 12/26 studies (CRP), 2/11 (fibrinogen) and 3/6 (IL-6). On random-effects meta-analysis of comparable studies, CRP was associated with an increased risk of recurrent stroke [pooled hazard ratio (HR) per 1 standard-deviation (SD) increase in log(e)-CRP (1.14, 95% CI 1.06-1.22, p < 0.01)] and MVEs (pooled HR 1.21, CI 1.10-1.34, p < 0.01). Fibrinogen was also associated with recurrent stroke (HR 1.26, CI 1.07-1.47, p < 0.01) and MVEs (HR 1.31, 95% CI 1.15-1.49, p < 0.01). Trends were identified for IL-6 for recurrent stroke (HR per 1-SD increase 1.17, CI 0.97-1.41, p = 0.10) and MVEs (HR 1.22, CI 0.96-1.55, p = 0.10). Conclusion Despite evidence suggesting an association between inflammatory markers and post-stroke vascular recurrence, substantial methodological heterogeneity was apparent between studies. Individual-patient pooled analysis and standardisation of methods are needed to determine the prognostic role of blood inflammatory markers and to improve patient selection for randomised trials of inflammatory therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available